Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27822290 | 0.92 | MTOR (0.55) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL4068051 | 0.85 | LMNA (0.55) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL24592166 | 0.84 | NPC1 (0.59) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL27841533 | 0.83 | NPC1 (0.44) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL3163930 | 0.81 | NPC1 (0.61) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL14562610 | 0.81 | NPC1 (0.61) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL491378 | 0.80 | NPC1 (0.65) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL4017346 | 0.80 | NPC1 (0.65) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL4206585 | 0.79 | NPC1 (0.58) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL10181786 | 0.79 | NPC1 (0.58) | NPC1RAB9ACA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1415986-B1 | SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20040259890-A1 | Spiro compounds | MSD K.K. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1415986-A1 | SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259890-A1 | Spiro compounds | OPRD1, PER2, OPRK1 | NPC1 1009/4885RAB9A 1702/4885CA12 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.